<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127841">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019875</url>
  </required_header>
  <id_info>
    <org_study_id>R01GM063666</org_study_id>
    <nct_id>NCT02019875</nct_id>
  </id_info>
  <brief_title>CYP3A4 Induction and Mineral Homeostasis</brief_title>
  <official_title>Hormonal Regulation of CYP3A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether changes in the activity of the enzyme
      CYP3A4 can change the Vitamin D and bone mineral homeostasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will receive one of six interventions for 14 days (determined by
      randomization):a). 200 mL of water once a day; b) rifampin 600 mg once a day; c) 200 mL of
      grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days; d)
      clarithromycin 250 mg twice a day; f) clarithromycin 250 mg twice a day plus rifampin 600 mg
      once a day.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>1, 25(OH) D3 Vitamin D</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>25(OH) D3 Vitamin D</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Hormone</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium, total</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium, ionized</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphate</measure>
    <time_frame>Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Vitamin D and Calcium Homeostasis</condition>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 mL of water once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampin 600 mg once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grapefruit Juice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mL of grapefruit juice once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grapefruit Juice Plus Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 250 mg twice a day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clarithromycin Plus Rifampin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <arm_group_label>Rifampin</arm_group_label>
    <arm_group_label>Grapefruit Juice Plus Rifampin</arm_group_label>
    <arm_group_label>Clarithromycin Plus Rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_label>Clarithromycin Plus Rifampin</arm_group_label>
    <other_name>Biaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Grapefruit Juice</intervention_name>
    <arm_group_label>Grapefruit Juice</arm_group_label>
    <arm_group_label>Grapefruit Juice Plus Rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with no history of significant medical conditions including cardiac,
             pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B
             or C

          -  Subjects will be males or females 18-60 years of age

          -  Subjects must read and understand English

          -  Subjects must be able to provide informed consent

          -  Subjects must be willing to avoid prescription medications, OTC drugs, dietary
             supplements and foods that are known to modulate CYP3A4 expression or activity

          -  Subjects must be willing to maintain a consistent consumption of calcium and Vitamin
             D during the study and maintain a daily logbook of their dietary consumption

          -  Women not currently pregnant or lactating. In addition, women participants of
             childbearing age must be willing to utilize a barrier method of birth control
             (sterilization will be acceptable)

          -  Subjects will have no known allergies to the study drugs to be used

          -  Subject's corrected QTc interval obtained by electrocardiogram will be ≤ 430 ms in
             men or ≤ 450 ms in women

        Exclusion Criteria:

          -  Subjects with any significant chronic medical condition, including cardiac,
             pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B
             or C

          -  Subjects less than 18 or greater than 60 years of age

          -  Subjects unable to read and understand English

          -  Subjects unable to provide informed consent

          -  Subjects unable to avoid prescription medications, OTC drugs, dietary supplements and
             foods that are known to modulate CYP3A4 expression or activity

          -  Subjects not willing to maintain a consistent consumption of calcium and Vitamin D
             during the study and maintain a daily logbook of their dietary consumption

          -  Women who are pregnant or lactating and women participants of childbearing age not
             willing to utilize a barrier method of birth control (sterilization will be
             acceptable)

          -  Subjects with allergies to rifampin, clarithromycin or grapefruit juice

          -  Potential participants will be excluded if they are concurrently participating in
             another research study

          -  Subjects with corrected QTc interval  &gt; 430 ms in men or &gt; 450 ms in women on
             electrocardiogram
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Thummel, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Collins, M.D.</last_name>
      <phone>206-616-3294</phone>
      <email>carolc3@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Thummel, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carol Collins, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian De Boer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Kenneth Thummel</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Pharmaceutics</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>CYP3A4</keyword>
  <keyword>Calcium</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
